Publikationen W. Löscher

Hampel, P., Johne, M., Gailus, B., Vogel, A., Schidlitzki, A., Gericke, B., Töllner, K., Theilmann, W., Käufer, C., Römermann, K., Kaila, K., & Löscher, W. (2021). Deletion of the Na-K-2Cl cotransporter NKCC1 results in a more severe epileptic phenotype in the intrahippocampal kainate mouse model of temporal lobe epilepsy. Neurobiology of Disease, 152: 105297. https://doi.org/10.1016/j.nbd.2021.105297
Details anzeigen
Hampel, P., Römermann, K., Gailus, B., Johne, M., Gericke, B., Kaczmarek, E., & Löscher, W. (2021). Effects of the NKCC1 inhibitors bumetanide, azosemide, and torasemide alone or in combination with phenobarbital on seizure threshold in epileptic and nonepileptic mice. Neuropharmacology, 185: 108449. https://doi.org/10.1016/j.neuropharm.2021.108449
Details anzeigen
Johne, M., Römermann, K., Hampel, P., Gailus, B., Theilmann, W., Ala-Kurikka, T., Kaila, K., & Löscher, W. (2020). Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective. Epilepsia: The Journal of the International League Against Epilepsy, 00: early access. https://doi.org/10.1111/epi.16778
Details anzeigen
Löscher, W., Sills, G. J., & White, H. S. (2021). The ups and downs of alkyl-carbamates in epilepsy therapy: How does cenobamate differ? Epilepsia: The Journal of the International League Against Epilepsy, 62(3), 596–614. https://doi.org/10.1111/epi.16832
Details anzeigen
Theilmann, W., Brandt, C., Bohnhorst, B., Winstroth, A.-M., Das, A. M., Gramer, M., Kipper, A., Kalesse, M., & Löscher, W. (2021). Hydrolytic biotransformation of the bumetanide ester prodrug DIMAEB to bumetanide by esterases in neonatal human and rat serum and neonatal rat brain: a new treatment strategy for neonatal seizures? Epilepsia: The Journal of the International League Against Epilepsy, 62(1), 269–278. https://doi.org/10.1111/epi.16746
Details anzeigen
Welzel, L., Bergin, D. H., Schidlitzki, A., Twele, F., Johne, M., Klein, P., & Löscher, W. (2021). Systematic evaluation of rationally chosen multitargeted drug combinations: a combination of low doses of levetiracetam, atorvastatin and ceftriaxone exerts antiepileptogenic effects in a mouse model of acquired epilepsy. Neurobiology of Disease, 149, 105227. https://doi.org/10.1016/j.nbd.2020.105227
Details anzeigen
Dabke, P. (2020). Mechanism of Ketogenic Diet: Impact of Beta – Hydroxybutyrate and Decanoic Acid on Sirtuins, Energy Metabolism and Cellular Lipids in a Murine Hippocampal Neuronal Cell Model. https://elib.tiho-hannover.de/receive/tiho_mods_00003661
Details anzeigen
Debski, K. J., Ceglia, N., Ghestem, A., Ivanov, A. I., Brancati, G. E., Bröer, S., Bot, A. M., Müller, J. A., Schoch, S., Becker, A., Löscher, W., Guye, M., Sassone-Corsi, P., Lukasiuk, K., Baldi, P., & Bernard, C. (2020). The circadian dynamics of the hippocampal transcriptome and proteome is altered in experimental temporal lobe epilepsy. Science Advances, 6(41: eaat5979). https://doi.org/10.1126/sciadv.aat5979
Details anzeigen
Gericke, B., Brandt, C., Theilmann, W., Welzel, L., Schidlitzki, A., Twele, F., Kaczmarek, E., Anjum, M., Hillmann, P., & Löscher, W. (2020). Selective inhibition of mTORC1/2 or PI3K/mTORC1/2 signaling does not prevent or modify epilepsy in the intrahippocampal kainate mouse model. Neuropharmacology, 162: 107817. https://doi.org/10.1016/j.neuropharm.2019.107817
Details anzeigen
Gericke, B., Römermann, K., Noack, A., Noack, S., Kronenberg, J., Blasig, I. E., & Löscher, W. (2020). A face-to-face comparison of claudin-5 transduced human brain endothelial (hCMEC/D3) cells with porcine brain endothelial cells as blood-brain barrier models for drug transport studies. Fluids and Barriers of the CNS, 17: 53. https://doi.org/10.1186/s12987-020-00212-5
Details anzeigen